Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00442832 · ClinicalTrials.gov registry record · Phase 2
TD-1792 in Gram-positive Complicated Skin and Skin Structure Infection
A Phase 2 study of Staphylococcal Skin Infection, sponsored by Theravance Biopharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 203
- Enrollment target
- 1
- Study location
NCT00442832 is a Phase 2 study of Staphylococcal Skin Infection that has completed, run by Theravance Biopharma. The registered enrollment target is 203 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00442832, a Phase 2 study of Staphylococcal Skin Infection, has completed, sponsored by Theravance Biopharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 203 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine whether TD-1792 is safe and effective when used to treat complicated skin and skin structure infections caused by Gram-positive bacteria.
Conditions Studied
Interventions
- DRUG Vancomycin
- DRUG TD-1792
Study Locations (1)
California
- Allan Churukian - National City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 203 participants |
| Start Date | 2006-12 |
| Est. Completion | 2007-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00442832
The ClinicalTrials.gov registry entry for NCT00442832 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 203 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Theravance Biopharma, which has 38 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Staphylococcal Skin Infection appearing as the primary indexed condition, and to 2 interventions - of which Vancomycin is the first listed.
NCT00442832 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT00442832 about?
NCT00442832 is a clinical study titled "TD-1792 in Gram-positive Complicated Skin and Skin Structure Infection". The purpose of this study is to determine whether TD-1792 is safe and effective when used to treat complicated skin and skin structure infections caused by Gram-positive bacteria.
What is the current status of trial NCT00442832?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 203 participants. The study started on 2006-12. Estimated completion is 2007-05.
What conditions does trial NCT00442832 study?
This clinical trial studies the following conditions: Staphylococcal Skin Infection.
What interventions are being tested in trial NCT00442832?
The interventions under investigation include: Vancomycin (DRUG), TD-1792 (DRUG).
Who is sponsoring clinical trial NCT00442832?
This trial is sponsored by Theravance Biopharma, which has 38 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00442832 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.